Sachmechi Issac, Reich David M, Aninyei Michael, Wibowo Francisca, Gupta Garima, Kim Paul J
Division of Endocrinology, Queens Hospital Center, Mount Sinai School of Medicine, Jamaica, New York 11432, USA.
Endocr Pract. 2007 Jul-Aug;13(4):345-9. doi: 10.4158/EP.13.4.345.
To examine retrospectively the effect of proton pump inhibitors (PPIs) on thyrotropin (thyroid-stimulating hormone or TSH) values in patients with hypothyroidism and normal TSH levels receiving levothyroxine (LT4) replacement therapy.
The data collection was done by retrospective review of electronic medical records from the period of December 2002 to August 2005 from patients with hypothyroidism who were receiving at least 25 mug of LT4 replacement daily at Queens Hospital Center. The first 92 patients meeting all inclusion and exclusion criteria were included in the study. The study group (N = 37) patient data were collected by selecting euthyroid patients who had received stable LT4 replacement for at least 6 months and in whom PPI therapy (lansoprazole) was later initiated. TSH levels were collected before and at least 2 months after the PPI treatment was started. The control group (N = 55) patient data were collected by reviewing TSH levels among euthyroid patients with a history of hypothyroidism receiving stable LT4 therapy and not receiving a PPI during the period of data collection. The statistical analysis was done by comparing the mean change in TSH level in each group with use of the Student t test.
In the study group, the mean change in the TSH level from before to at least 2 months after initiation of PPI therapy, 0.69 +/- 1.9 micro IU/mL, was statistically significant (P = 0.035). In the control group, the mean change in the TSH level during the study period, 0.11 +/- 1.06 micro IU/mL, was not statistically significant (P = 0.45).
To our best knowledge, this is the first study in humans with hypothyroidism demonstrating the effect of PPIs on serum TSH levels. PPIs should be added to the list of medications affecting the level of thyroid hormone in patients with hypothyroidism treated with LT4 replacement. Patients with hypothyroidism and normal TSH values during LT4 replacement therapy may need additional thyroid function testing after treatment with PPIs and may need adjustment of their LT4 dose.
回顾性研究质子泵抑制剂(PPI)对接受左甲状腺素(LT4)替代治疗的甲状腺功能减退且促甲状腺激素(甲状腺刺激激素或TSH)水平正常患者的TSH值的影响。
通过回顾2002年12月至2005年8月期间在皇后医院中心接受至少25微克LT4替代治疗的甲状腺功能减退患者的电子病历进行数据收集。纳入符合所有纳入和排除标准的前92例患者。研究组(N = 37)的患者数据通过选择甲状腺功能正常且接受稳定LT4替代治疗至少6个月且后来开始PPI治疗(兰索拉唑)的患者收集。在开始PPI治疗前及开始治疗后至少2个月收集TSH水平。对照组(N = 55)的患者数据通过回顾在数据收集期间有甲状腺功能减退病史且接受稳定LT4治疗但未接受PPI的甲状腺功能正常患者的TSH水平收集。使用Student t检验比较每组TSH水平的平均变化进行统计分析。
在研究组中,从开始PPI治疗前到至少2个月后的TSH水平平均变化为0.69±1.9微国际单位/毫升,具有统计学意义(P = 0.035)。在对照组中,研究期间TSH水平的平均变化为0.11±1.06微国际单位/毫升,无统计学意义(P = 0.45)。
据我们所知,这是第一项在甲状腺功能减退患者中证明PPI对血清TSH水平有影响的人体研究。PPI应添加到影响接受LT4替代治疗的甲状腺功能减退患者甲状腺激素水平的药物清单中。在LT4替代治疗期间甲状腺功能减退且TSH值正常的患者在用PPI治疗后可能需要额外的甲状腺功能测试,并且可能需要调整他们的LT4剂量。